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Background
While transthyretin (TTR) amyloidosis is usually charac-
terized by peripheral and autonomic neuropathy, a
majority of patients also have evidence of restrictive car-
diomyopathy. In addition, amyloid cardiomyopathy may
occur in the elderly without the presence of a mutant
form of TTR. Both the hereditary and wild-type TTR
amyloidosis are characterized by progressive restrictive
cardiomyopathy. The disease usually progresses over a
five to ten year period from time of diagnosis to demise
from congestive heart failure.
At present there are ongoing pharmaceutical studies
to suppress the synthesis of TTR by the liver using anti-
sense oligonucleotides or siRNA. Both types of agents
have been shown to be effective in lowering blood levels
of TTR but efficacy measured by inhibition of progres-
sion of disease has not yet been established. The present
study is an investigator sponsored Phase-2 study to
determine the safety and tolerability of an ISIS genera-
tion 2.0 antisense oligonucleotide in patients with mod-
erate to advanced TTR cardiomyopathy.
Methods
Subjects are admitted to the study with biopsy proven
transthyretin amyloidosis (ATTR) and a left ventricular
(LV) wall thickness of  1.3 cm. Safety parameters are
observed over a 24-month period. Echocardiography is
conducted at baseline and at 6-month intervals. Cardiac
MRI is obtained at baseline and 12-month intervals.
ISIS-TTRRx 300 mg is administered weekly by subcuta-
neous injection.
Results
To date, ten patients have been admitted to the study.
Five patients have completed greater than 6-months on
drug. TTR plasma levels have fallen steadily with reduc-
tion up to 88% and a mean suppression of 78% by 39-
weeks. No serious adverse events have occurred.
Conclusion
ISIS-TTRRx appears to be well tolerated by patients
with ATTR cardiomyopathy. Efficacy evaluation awaits
longitudinal studies determining stability of LV mass.
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